To evaluate the effect of eplerenone on patients with long-term recurring central serous chorioretinopathy (CSC).
In this retrospective case series, 11 patients with chronic recurring CSC were included. The main focus was to include patients who had undergone photodynamic therapy (4 patients), had undergone anti–vascular endothelial growth factor treatment (3 patients), or had several episodes of CSC in the past (4 patients) (mean age 60 years; SD 9.7, range 47-76).
Four patients (36.4%) had full resorption of neurosensory detachment under therapy of eplerenone with improvement of vision, while 4 more patients had improvement of vision despite residual edema. Eight patients (73%) had improved visual acuity (VA) at the end of eplerenone therapy, 2 patients had no change in VA, and 1 patient decreased VA. Mean time of treatment was 10.6 ± 9.9 weeks (range 3-38 weeks). All patients showed subretinal deposits, with 6 of them having hyperautofluorescent subretinal deposits.
Eplerenone represents a new treatment option for patients with CSC. Our data indicate a good response in those patients, leading to improvement of VA in 73% of patients.
Eur J Ophthalmol 2016; 26(5): 479 - 484
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsChristoph Leisser, Nino Hirnschall, Christoph Hackl, Pia Plasenzotti, Oliver Findl
- • Accepted on 25/11/2015
- • Available online on 17/12/2015
- • Published in print on 04/08/2016
This article is available as full text PDF.
- Leisser, Christoph [PubMed] [Google Scholar] 1
- Hirnschall, Nino [PubMed] [Google Scholar] 1
- Hackl, Christoph [PubMed] [Google Scholar] 1
- Plasenzotti, Pia [PubMed] [Google Scholar] 2
- Findl, Oliver [PubMed] [Google Scholar] 1, 3, * Corresponding Author (email@example.com)
VIROS-Vienna Institute for Research in Ocular Surgery, A Karl Landsteiner Institute, Hanusch Hospital, Vienna - Austria
1st Medical Department, Hanusch Hospital, Vienna - Austria
Moorfields Eye Hospital NHS Foundation Trust, London - UK